We report a case of metachronous second primary lung cancer; it was initially clinically favored as progression of primary disease and finally diagnosed as a second primary lung cancer by surgical resection at salvage setting. A 73-year-old man was diagnosed with stage IV lung adenocarcinoma at initial presentation. He underwent two lines of chemotherapy, and the tumors regressed dramatically. However, the residual lung mass shadow expanded after 22 months. We performed resection at salvage setting. The gene status and histological subtype were not identical with that of the primary tumor, suggesting this to be a second primary lung cancer.
Introduction
Recently, surgical treatment for the progressive and/or residual disease after radical chemotherapy and/or radiation has been termed as "salvage surgery". The patient selection and practical contributions for outcomes remain unclear.
In clinical practice, distinguishing between a second primary lung cancer and progressive disease is sometimes hard. It is necessary to take into account all clinical, pathological, and biomarker information to make an accurate diagnosis of multiple lesions [1] ; meanwhile, the indications of the salvage surgery are sometimes determined mainly on the basis of clinical findings without rebiopsy.
Case report
A 73-year-old man complained of a stiff neck and was referred to the previous doctor. Chest computed tomography (CT) demonstrated a solid mass shadow in the right lower lobe of his lung measuring 6.4 cm (Fig. 1a) . Bilateral hilar and mediastinal lymphadenopathy were identified, which had extended to the left side of his neck. The pathological specimen of the neck biopsy was revealed to be adenocarcinoma consistent with the metastasis from lung cancer (Fig. 2a) . He was referred to our hospital for further examinations and treatment.
18-Fluoro-deoxyglucose positron-emission tomographycomputed tomography (18FDG-PET/CT) scanning revealed FDG uptake in the mass of the right lung, hilum/mediastinum, and the left side of the neck (Fig. 1d) . We diagnosed his disease as stage IV (cT2bN3M1b, IV, UICC TNM 7th) lung adenocarcinoma. The tumor specimen was examined genetically, being negative for alterations in EGFR, KRAS, and ALK genes.
He underwent 4 cycles of carboplatin (AUC6) and pemetrexed (500 mg/m 2 ) treatment as the first-line chemotherapy. However, the tumor progressed gradually after 4 cycles of chemotherapy. Subsequently, he underwent 4 cycles of docetaxel (60 mg/m 2 ) as the second-line treatment, and the tumors regressed dramatically. The therapeutic effect was PR, with almost complete remission (Fig. 1b) . Twenty-two months after the completion of the second-line chemotherapy, the chest CT scan revealed an expansion of the residual shadow measuring 4.9 cm (Fig. 1c) . Wholebody examinations, including CT and FDG-PET, and brain MRI were performed. Finally, we diagnosed his disease as local progression of the primary site, ycT3N0M0, stage IIB (Fig. 1e) .
We performed a right S6 segmentectomy and combined chest wall resection including the 5th ribs as a salvage treatment. Pathological diagnosis of the resected specimens was solid predominant adenocarcinoma (Fig. 2b) . The tumor cells were weakly positive for thyroid transcription factor-1 (TTF-1) staining (Fig. 2d) , which was apparently a different phenotype from the primary tumor (Fig. 2c) . Furthermore, genetic exploration revealed a KRAS G12D mutation and a p53 I272M mutation that were not identical with the status of the primary tumor, wherein both KRAS and p53 were wild type. Alterations in EGFR, ALK, HER2, MET, ROS1, and BRAF genes were not detected in either specimen. Accordingly, we diagnosed his disease as a metachronous second primary lung cancer and not progression of the primary tumor.
Moreover, 3 months after pulmonary resection, he experienced metastases in his right fibula and ipsilateral hilum, which were diagnosed as recurrence of the second cancer on the basis of the pathological and genetic findings of the hilum biopsy specimen. The chemotherapy has since been restarted.
Discussion
In clinical practice, it is sometimes challenging to distinguish between a primary lung cancer that has metastasized and an additional primary tumor. The diagnoses can strongly affect the treatment strategy as well as the prognosis of the patient.
In the present case, considering that the second tumor developed from the residual site of the primary one, we made the diagnosis of a re-progression of the primary cancer. We initially performed pulmonary resection as a salvage treatment. Eventually, the surgical specimen was diagnosed as a second primary tumor, not re-progression, on the basis of the distinct histologic subtype and biomarker pattern. If we could have diagnosed the second primary lung adenocarcinoma before surgical treatment, we may have considered an option other than a segmentectomy.
In 1975, Martini and Melamed suggested the definition of the criteria for diagnosing multiple primary lung cancer, and they have been widely used in our clinical practice [2] . These criteria were mainly based on clinical and histologic factors. At present, while we have utilized biomarker analyses, there are no other confirmed standards in diagnosing multiple primary lung cancers. The IASLC Lung Cancer Staging Project proposed a criterion to distinguish second primary lung cancers from a primary cancer. According to them, we should base our decision on the experienced multidisciplinary team taking into account various factors (e.g., clinical, imaging, histologic, and genetic factors); therefore, a comprehensive judgment is required to make the diagnosis.
Although clinical findings and adenocarcinoma histology were consistent with re-progression of the primary tumor in the present case, discrepancies in KRAS and p53 status revealed a different genotype from the primary tumor. Those findings eventually led us to a diagnosis of a second primary lung cancer that had developed from the residual site of the primary tumor.
Indeed, several authors reported as low as 13.6-31% of discordance in KRAS status between the primary lesion and metastatic lesions [3, 4] . Kalikaki et al. have documented that
